JACC This Week

In this episode, Dr. Valentin Fuster discusses five key studies from the January 2025 JACC issue, covering advancements in coronary angioplasty, revascularization strategies for STEMI, machine learning for ICD patient outcomes, thromboxane's link to heart failure, and TAVR valve types and anesthesia approaches. These studies provide valuable insights into improving cardiovascular care and treatment.

In this episode, Dr. Valentin Fuster discusses the five-year results of the SOFT TAVI trial, which compared self-expanding and balloon-expanding valves for transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis. The findings reveal similar long-term outcomes for both valve types and anesthesia strategies, with subtle differences in stroke rates and pacemaker implantations, emphasizing the growing safety and efficacy of conscious sedation in TAVR procedures.

In this episode, Dr. Valentin Fuster discusses a groundbreaking study that uses machine learning to predict mortality and hospitalization risks in patients with implantable cardioverter defibrillators (ICDs). By leveraging large datasets and time-varying ICD data, the study developed a robust predictive model, though challenges remain regarding data gaps and its applicability to diverse patient populations.

In this episode, Dr. Valentin Fuster discusses a study published in the Journal of the American College of Cardiology examining the link between urinary thromboxane B2 metabolites and the risk of developing heart failure. The research suggests that high levels of these metabolites, potentially from the myocardium or other organs rather than platelets, are associated with an increased risk of heart failure, offering a potential new biomarker for early detection and targeted prevention strategies.

In this episode, Dr. Valentin Fuster discusses a comprehensive network meta-analysis published in JACC, which evaluates the optimal strategy for complete revascularization in patients with STEMI and multi-vessel disease. The study concludes that both immediate and staged complete revascularization improve patient outcomes over partial revascularization, with no significant advantage between angiographic and functional guidance, suggesting that angiographic guidance alone may be sufficient in clinical practice.

In this episode, Dr. Valentin Fuster discusses the findings of a major randomized trial examining the use of drug-coated balloons (DCB) in treating side branch stenosis during coronary bifurcation procedures. The study suggests that DCBs offer better one-year outcomes compared to non-coated balloons, showing a significant reduction in myocardial infarction rates, but highlights ongoing challenges in managing bifurcation lesions, especially considering the high cost and potential risks.

In this podcast, Dr. Valentin Fuster discusses a study on the long-term outcomes of two surgical approaches—anatomic and physiologic repair—for congenitally corrected transposition of the great arteries. The findings suggest that while the complex anatomic repair offers better survival and reintervention-free outcomes, patient selection is crucial, with careful consideration needed, especially for asymptomatic infants or those with preoperative pulmonary artery banding.

In this podcast, Dr. Valentin Fuster discusses a study on the significant impact of seasonal influenza on mortality and hospitalizations among patients with heart failure. The research highlights that influenza is responsible for substantial excess deaths and hospitalizations in this vulnerable group, emphasizing the need for better vaccination uptake and preventive measures to reduce these risks.

In this podcast, Dr. Valentin Fuster discusses a study on the impact of renal and liver function on clinical outcomes following tricuspid valve transcatheter H2O repair in patients with severe tricuspid regurgitation. While the study found no significant differences in organ function between repair and control groups at 12 months, successful repairs showed small but favorable improvements in kidney and liver function, suggesting potential long-term benefits in reducing heart failure hospitalizations and mortality.

In this podcast, Dr. Valentin Furster discusses a groundbreaking study on the role of oxidized phospholipids in calcific aortic valvular disease, highlighting their significant association with disease prevalence and progression. The findings suggest that targeting oxidized phospholipids, not just the Lp(a) particle, could offer a promising new therapeutic approach to treat this condition.